Clinical

Articles

How will biosimilars continue to affect the prescription product market in 2021?

Biosimilars May Lead to Improved Competition and Lower Costs

The advent of generic and biosimilar medicines for novel treatments has helped bridge the gap in the delivery of cancer care between the United States and India, according to the study. 

Study Compares Cost, Accessibility of Novel Cancer Drugs in US and India

In studies presented this month at the European E-Congress of Rheumatology 2020, investigators revealed positive findings for the infliximab biosimilar CT-P13 (Inflectra, Remsima), which is developed by Celltrion of Incheon, Republic of Korea.


Studies Reveal Positive Results for Infliximab Biosimilar

Rituximab-abbs (Truxima) is the only biosimilar to the reference product rituximab (Rituxan). 

Rituximab Biosimilar Now Available in United States for Rheumatoid Arthritis

Merck has announced the US launch of trastuzumab-dttb (Ontruzant), a biosimilar to trastuzumab (Herceptin), in both 150-mg single-dose vials and 420-mg multiple-dose vials.

Merck Announces US Launch of Trastuzumab Biosimilar

Officials with the FDA have approved a 420-mg multi-dose of trastuzumab-bttb (Ontruzant, Samsung Bioepis), a biosimilar referencing trastuzumab (Herceptin).

FDA Approves 420-mg Multi-Dose Vial of Trastuzumab Biosimilar

Pfizer announced the introduction of 3 new oncology biosimilars to the US market at a substantially discounted price.

Pfizer Announces US Launch of 3 New Oncology Biosimilars

FDA Approves Amgen’s Infliximab-axxq

Pfizer Gains FDA Approval for Humira Biosimilar 

Biosimilars may need more time to devleop in the market.